CD274 and familial pancreatic carcinoma: A variety of monoclonal antibodies against PD-1 or PD-L1, such as Opdivo and Atezolizumab, have been successfully developed as promising immunotherapy drugs in non-small cell lung cancer, pancreatic cancer, breast cancer, colorectal cancer, and other solid tumors10–12.